SCHEMBL17878770

SCHEMBL17878770

CCC[C@H](C)OC(=O)CCC(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC2 Q92769 2/20 0.41
FFAR3 O14843 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
EGLN1 Q9GZT9 2/20 0.41
KDM6B O15054 1/20 0.41
KDM5C P41229 1/20 0.41
PHF8 Q9UPP1 1/20 0.41
KDM2A Q9Y2K7 1/20 0.41
FAAH O00519 4/20 0.40
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
ALDH1A1 P00352 2/20 0.39
GABRP O00591 2/20 0.39
GABRD O14764 2/20 0.39
GABRA1 P14867 2/20 0.39
GABRB1 P18505 2/20 0.39
GABRG2 P18507 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17860864 1.00 LMNA (0.41) LMNAHDAC1HDAC2FFAR3HDAC3
SCHEMBL7696577 1.00 LMNA (0.41) LMNAHDAC1HDAC2FFAR3HDAC3
SCHEMBL7696578 0.92 LMNA (0.47) LMNAHDAC1HDAC2FAAHCNR1
SCHEMBL27554262 0.89 LMNA (0.52) LMNAALDH1A1TDP1AKR1B1FFAR4
SCHEMBL1713746 0.89 FAAH (0.49) LMNAFAAHCNR1CNR2ALDH1A1
SCHEMBL10555566 0.89 TSHR (0.48) LMNAALDH1A1TDP1AKR1B1FFAR4
SCHEMBL28371305 0.87 LMNA (0.55) LMNAALDH1A1TDP1AKR1B1FFAR4
SCHEMBL28373043 0.87 LMNA (0.55) LMNAALDH1A1TDP1AKR1B1FFAR4
SCHEMBL28367507 0.87 LMNA (0.55) LMNAALDH1A1TDP1AKR1B1FFAR4
SCHEMBL28562346 0.85 FAAH (0.58) LMNAFAAHCNR1CNR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9771394-B2 Antimicrobial polymyxins for treatment of bacterial infections MICURX PHARMACEUTICALS, INC. (KY) 2017-09-26 US disclosed
US-9771394-B2 Antimicrobial polymyxins for treatment of bacterial infections MICURX PHARMACEUTICALS, INC. (KY) 2017-09-26 US disclosed
US-20160185823-A1 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS MICURX PHARMACEUTICALS, INC. 2016-06-30 US disclosed
US-20160185823-A1 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS MICURX PHARMACEUTICALS, INC. 2016-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185823-A1 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS VIP, AQP1, PEF1 LMNA 660/4885HDAC1 2333/4885HDAC2 3355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.